Susanne Graslund
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Year:
2026
Objectives Autoantibodies targeting melanoma differentiation associated protein 5 (MDA5) are strongly associated with dermatomyositis (DM) and may contribute to its pathogenesis. Here we aimed to investigate MDA5 + B cells, their phenotype and generate MDA5 monoclonal antibodies to assess their epitope specificity. Methods MDA5-reactive B cells were captured from peripheral blood of patients with anti-MDA5 + DM (n=3) using an MDA5-fluorescent probe. B cell receptor (BCR) sequences were analysed from single-sorted B cells (n=240). Selected clones were re-expressed as IgG1 monoclonal antibodies (mAbs, n=23). Reactivity was assessed using recombinant MDA5 protein constructs, peptide epitope mapping, ELISA, western blot and a commercial line blot assay. Results Of 240 anti-MDA5 + sorted B cells, 23 BCRs were re-expressed as mAbs, two of which showed high reactivity and specificity for MDA5. These antibody sequences originated from one CD19 + IgD - CD27 - CD38 + and one CD19 + IgD - CD27 + CD38 + IgG + B cell with low somatic hypermutation (SHM). Both mAbs had nanomolar apparent affinity and bound to sites within the helicase domains of the MDA5 protein but with distinct epitope recognition. Serology screening confirmed targeting of a linear epitope identified in the mAb studies. Conclusion Our results show that anti-MDA5 + B cells recognize the helicase domains, which are the enzymatically active domains of the protein. These results have implications for understanding the etiopathology of anti-MDA5 + DM and development of new antigen-specific therapies.
Year:
2025
Genetic studies have identified hundreds of risk genes for neurodegenerative diseases, yet translating these variants into disease mechanisms remains limited by incomplete knowledge of the protein products. Here, we present the ALS-Reproducible Antibody Platform (ALS-RAP), a systematic effort to characterize 303 antibodies targeting 33 amyotrophic lateral sclerosis (ALS) risk genes: ACSL5, ALS2, ANG, ANXA11, ATXN2, C9orf72, CAV1, CCNF, CHCHD10, CHMP2B, FIG4, FUS, HNRNPA1, HNRNPA2B1, KIF5A, LGALS1, MATR3, NEK1, OPTN, PFN1, SETX, SIGMAR1, SOD1, SPG11, SQSTM1, TAF15, TARDBP, TBK1, TIA1, TUBA4A, UBQLN2, VAPB, and VCP using knockout-based characterization to identify high-quality reagents in common applications. Using these antibodies, we profiled protein expression across human iPSC-derived and primary neurological cell types. Protein-level analyses revealed diverse cell type-specific expression patterns, with subsets of ALS-associated proteins enriched in glial or neuronal populations. This work provides a validated antibody toolbox and ALS protein resource for translating genetic risk into mechanistic insights.
Year:
2025
Collaborators (19)
Carolyn Marks
Karolinska Institutet
Thomas M. Durcan
Associate Professor
Montreal Neurological Institute and Hospital
Charlotta Preger
Karolinska Institutet
Luke Michael Healy
-
Peter S. McPherson
McGill University
Ingrid Lundberg
Professor
Karolinska Institutet
Carl Laflamme
Assistant Professor
University of Ottawa
Karine Chemin
Associate Professor at Karolinska Institutet
Karolinska Institutet
Opher Gileadi
Head, Protein Sciences
Karolinska Institutet
Helena Idborg
Karolinska Institutet
Edward A. Fon
Professor
Montreal Neurological Institute and Hospital
Elisabet Svenungsson
Karolinska Institutet
Radiosa Gallini
Uppsala University
Vijay Joshua
Karolinska Institutet
Vivianne Malmström
Professor at Karolinska Institutet
Karolinska Institutet
Guy A Rouleau
Professor
McGill University
Brian D. Marsden
Associate Professor, Research Informatics
University of Oxford
Begum Horuluoglu
Assistant Professor
Karolinska Institutet
Harvinder Virk
NIHR Academic Clinical Lecturer (Respiratory Medicine)
University of Leicester
Make your next move.
Prepare your application
Review drafts before you send them.